Close Menu

After winning the bidding war for Oxford GlycoSciences in April, Celltech announced its proteomics division will be divested, in presenting its plans for the company at its annual general meeting last month. Meanwhile, the integration of OGS’ business is going full steam ahead.

As of last week, Celltech was close to owning 90 percent of OGS’ shares, according to Richard Bungay, Celltech’s director for corporate communications and strategic planning. Once the company owns 90 percent of the shares, it can force the remaining shareholders to sell.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.